- Home
- IGR vs TERN Comparison
IGR vs TERN Comparison
Compare IGR & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGR
- TERN
- Stock Information
- Founded
- IGR 2004
- TERN 2017
- Country
- IGR United States
- TERN United States
- Employees
- IGR N/A
- TERN N/A
- Industry
- IGR Finance Companies
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- IGR Finance
- TERN Health Care
- Exchange
- IGR Nasdaq
- TERN Nasdaq
- Market Cap
- IGR 776.6M
- TERN 713.2M
- IPO Year
- IGR N/A
- TERN 2021
- Fundamental
- Price
- IGR $5.03
- TERN $8.39
- Analyst Decision
- IGR
- TERN Buy
- Analyst Count
- IGR 0
- TERN 7
- Target Price
- IGR N/A
- TERN $14.99
- AVG Volume (30 Days)
- IGR 747.7K
- TERN 1.1M
- Earning Date
- IGR 01-01-0001
- TERN 11-11-2025
- Dividend Yield
- IGR 13.93%
- TERN N/A
- EPS Growth
- IGR N/A
- TERN N/A
- EPS
- IGR N/A
- TERN N/A
- Revenue
- IGR N/A
- TERN N/A
- Revenue This Year
- IGR N/A
- TERN N/A
- Revenue Next Year
- IGR N/A
- TERN N/A
- P/E Ratio
- IGR N/A
- TERN N/A
- Revenue Growth
- IGR N/A
- TERN N/A
- 52 Week Low
- IGR $3.88
- TERN $1.87
- 52 Week High
- IGR $5.70
- TERN $9.03
- Technical
- Relative Strength Index (RSI)
- IGR 48.16
- TERN 58.46
- Support Level
- IGR $4.91
- TERN $7.91
- Resistance Level
- IGR $5.20
- TERN $9.03
- Average True Range (ATR)
- IGR 0.08
- TERN 0.42
- MACD
- IGR -0.01
- TERN -0.01
- Stochastic Oscillator
- IGR 43.00
- TERN 59.43
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.